Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents

Rhea-AI Summary

Avinger (NASDAQ:AVGR) has announced the issuance of a new U.S. patent and the allowance of five additional U.S. patents, expanding its intellectual property protection for image-guided systems and devices in vascular disease treatment. The newly issued patent, No. 12,089,838, covers an "Atherectomy Catheter with Laterally-Displaceable Tip". The five allowed patents relate to:

• Optical Coherence Tomography for Biological Imaging
• Atherectomy Catheter Drive Assemblies
• Occlusion Crossing Devices
• Atherectomy Catheter with Shaped Distal Tip

With these additions, Avinger now holds 74 issued and allowed patents in the U.S., strengthening its position in the medical device market for vascular disease diagnosis and treatment.

Positive

• Issuance of a new U.S. patent for atherectomy catheter technology
• Allowance of five additional U.S. patents for various medical device technologies
• Expansion of intellectual property protection for proprietary image-guided systems and devices
• Increase in total U.S. patents to 74, strengthening market position

Negative

• None.

Medical Research Analyst

The issuance of a new U.S. patent and allowance of five additional patents for Avinger is a significant development in the medical device industry. These patents strengthen Avinger's position in intravascular imaging and treatment technologies, particularly in atherectomy and optical coherence tomography (OCT).

The expanded IP portfolio, now totaling 74 issued and allowed patents, demonstrates Avinger's commitment to innovation in vascular disease treatment. This could potentially increase barriers to entry for competitors and solidify Avinger's market position. However, it's important to note that while patents are valuable, their true worth lies in successful commercialization and market adoption of the protected technologies.

For investors, this news indicates Avinger's ongoing R&D efforts and could be seen as a positive long-term indicator. Yet, it's important to consider how these patents will translate into revenue growth and market share gains in the competitive medical device landscape.

Legal Expert

The issuance and allowance of multiple patents for Avinger is a strategically significant legal development. This expansion of their intellectual property portfolio provides broader protection for their core technologies and potential future innovations.

The diverse range of patents, covering aspects from atherectomy catheters to OCT systems, suggests a comprehensive IP strategy. This could potentially deter competitors from entering certain technological areas or force them to seek licensing agreements with Avinger.

However, it's important to note that patent issuance doesn't guarantee market exclusivity. The strength and enforceability of these patents will be key factors in their practical value. Investors should monitor how Avinger leverages this expanded IP portfolio in the market and any potential patent litigation that may arise as the company seeks to protect its technological advantages.

Financial Analyst

The expansion of Avinger's patent portfolio is a positive development from a financial perspective, albeit with some caveats. Strengthened IP protection can potentially lead to increased market share and improved profit margins by reducing competition and creating opportunities for licensing revenues.

However, investors should be cautious about overvaluing patent announcements. The true financial impact will depend on Avinger's ability to commercialize these protected technologies effectively. It's important to monitor upcoming financial reports for signs of revenue growth or improved profitability that can be attributed to these patents.

Additionally, while a strong patent portfolio can be attractive for potential partnerships or acquisitions, it also involves ongoing costs for maintenance and potential litigation. Investors should consider the balance between IP-related expenses and returns in assessing the long-term financial implications of this expanded patent protection.

REDWOOD CITY, CA / ACCESSWIRE / September 18, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of a new U.S. patent and the allowance of five additional U.S. patents that are expected to issue over the next four months. These patents expand intellectual property protection for Avinger's proprietary image-guided system and devices for both peripheral and coronary applications.

The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,089,838 titled "Atherectomy Catheter with Laterally-Displaceable Tip" on September 17, 2024. Avinger has also received notices of allowance from the USPTO for five additional U.S. patents providing coverage for Avinger's proprietary optical coherence tomography (OCT) system and image-guided devices, including:

• U.S. Application no. 18/499,555, Optical Coherence Tomography for Biological Imaging

• U.S. Application no. 17/645,722, Atherectomy Catheter Drive Assemblies

• U.S. Application no. 17/209,168, Occlusion Crossing Devices

• U.S. Application no. 17/455,655, Atherectomy Catheter with Shaped Distal Tip

• U.S. Application no. 17/046,066, Occlusion Crossing Devices

"Providing robust intellectual property protection for our proprietary devices and technologies is a critical part of our business strategy," commented Jeff Soinski, Avinger's President and CEO. "With the addition of these new patents, we now have 74 issued and allowed patents in the U.S. This growing intellectual property portfolio is a testimony to the creativity of our R&D team and the uniqueness of our innovative solutions for the treatment of vascular disease."

About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first image-guided, catheter-based system for the diagnosis and treatment of patients with vascular disease in the peripheral and coronary arteries. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox series of imaging consoles, the Ocelot and Tigereye® family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices for the treatment of peripheral artery disease (PAD), estimated to affect more than 200 million people worldwide. Avinger is developing its first product application for the treatment of coronary artery disease (CAD), an image-guided system for CTO-crossing in the coronary arteries, which provides the opportunity to redefine a large and underserved market. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Follow Avinger on X and Facebook.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the future issuance of our allowed patents in the U.S. and the ability of our patents to protect our OCT system and image-guided devices. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; the resource requirements related to Pantheris, Tigereye and our Lightbox imaging console; the outcome of clinical trial results; the adoption of our products by physicians; our ability to obtain regulatory approvals for our products; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2024, and Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward- looking statements.

Investor Contact:
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

Public Relations Contact:
Phil Preuss
Chief Marketing Officer
Avinger, Inc.
(650) 241-7942
pr@avinger.com

SOURCE: Avinger, Inc.

View the original press release on accesswire.com

FAQ

How many new patents did Avinger (AVGR) announce on September 18, 2024?

Avinger announced the issuance of 1 new U.S. patent and the allowance of 5 additional U.S. patents, totaling 6 new patents.

What is the title of the newly issued U.S. patent for Avinger (AVGR)?

The newly issued U.S. patent is titled 'Atherectomy Catheter with Laterally-Displaceable Tip' with patent number 12,089,838.

How many total U.S. patents does Avinger (AVGR) now have after this announcement?

After this announcement, Avinger now has 74 issued and allowed patents in the United States.

What areas of technology do Avinger's (AVGR) new patents cover?

The new patents cover technologies related to atherectomy catheters, optical coherence tomography for biological imaging, catheter drive assemblies, and occlusion crossing devices.